AP133A - Antiparasitical Formulations - Google Patents
Antiparasitical Formulations Download PDFInfo
- Publication number
- AP133A AP133A APAP/P/1990/000174A AP9000174A AP133A AP 133 A AP133 A AP 133A AP 9000174 A AP9000174 A AP 9000174A AP 133 A AP133 A AP 133A
- Authority
- AP
- ARIPO
- Prior art keywords
- avermectin
- ethyl oleate
- sesame oil
- compound
- animals
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 35
- 238000009472 formulation Methods 0.000 title description 28
- 230000002141 anti-parasite Effects 0.000 title description 4
- 239000000243 solution Substances 0.000 claims abstract description 20
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 17
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 17
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 17
- 239000008159 sesame oil Substances 0.000 claims abstract description 17
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000005660 Abamectin Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 abstract description 7
- 244000045947 parasite Species 0.000 abstract description 5
- 229940125687 antiparasitic agent Drugs 0.000 abstract description 4
- 239000012899 standard injection Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 22
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 241000238876 Acari Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 5
- 229940102223 injectable solution Drugs 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 244000078703 ectoparasite Species 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229940007210 ivomec Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 241000238680 Rhipicephalus microplus Species 0.000 description 2
- 241000243774 Trichinella Species 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229940074076 glycerol formal Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960002418 ivermectin Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001147657 Ancylostoma Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000243990 Dirofilaria Species 0.000 description 1
- 241000498256 Enterobius Species 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000920471 Lucilia caesar Species 0.000 description 1
- 241000498271 Necator Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000207961 Sesamum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 244000000050 gastrointestinal parasite Species 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898908071A GB8908071D0 (en) | 1989-04-11 | 1989-04-11 | Antiparasitic formulations |
| SG27894A SG27894G (en) | 1989-04-11 | 1994-02-22 | Injectable compositions containing 25-cyclohexyl-avermectin B1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9000174A0 AP9000174A0 (en) | 1990-04-30 |
| AP133A true AP133A (en) | 1991-06-05 |
Family
ID=26295191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1990/000174A AP133A (en) | 1989-04-11 | 1990-04-09 | Antiparasitical Formulations |
Country Status (16)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19613972A1 (de) * | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| WO1997046204A2 (en) * | 1996-06-05 | 1997-12-11 | Ashmont Holdings Limited | Injectable compositions |
| DE19638045A1 (de) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
| KR20000025762A (ko) * | 1998-10-14 | 2000-05-06 | 유충식 | 이버멕틴류의 가용화 조성물 |
| GB9827727D0 (en) | 1998-12-16 | 1999-02-10 | Pfizer Ltd | Antiparasitic formulations |
| AU2009271299B2 (en) * | 2008-06-24 | 2014-09-11 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic formulations |
| US8551962B2 (en) * | 2009-02-16 | 2013-10-08 | Zoetis Llc | High dosage doramectin formulation |
| EP2485725A2 (en) * | 2009-10-07 | 2012-08-15 | Wyeth LLC | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0316124A2 (en) * | 1987-11-09 | 1989-05-17 | Pfizer Inc. | Ethylated avermectins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2166436B (en) * | 1984-09-14 | 1989-05-24 | Glaxo Group Ltd | Antibiotic compounds and their preparation |
| IL78621A (en) * | 1985-04-30 | 1991-06-30 | American Cyanamid Co | Mylbemycin analogs,their preparation and pesticidal compositions containing them |
| US4707470A (en) * | 1985-05-17 | 1987-11-17 | Smithkline Beckman Corporation | Polyene antibiotic emulsion formulation |
| EP0285561A3 (de) * | 1987-03-27 | 1989-10-25 | Ciba-Geigy Ag | Parasitizide und insektizide Milbemycin-Derivate |
-
1990
- 1990-04-06 EP EP90303716A patent/EP0393890B1/en not_active Expired - Lifetime
- 1990-04-06 ES ES90303716T patent/ES2052173T3/es not_active Expired - Lifetime
- 1990-04-06 DK DK90303716.6T patent/DK0393890T3/da active
- 1990-04-09 AP APAP/P/1990/000174A patent/AP133A/en active
- 1990-04-10 NO NO901637A patent/NO175882C/no not_active IP Right Cessation
- 1990-04-10 FI FI901816A patent/FI92015C/fi active IP Right Grant
- 1990-04-10 AU AU53119/90A patent/AU609660B2/en not_active Ceased
- 1990-04-10 RU SU904743681A patent/RU1836084C/ru active
- 1990-04-10 OA OA59772A patent/OA09203A/xx unknown
- 1990-04-11 CN CN90102072A patent/CN1035356C/zh not_active Expired - Lifetime
- 1990-04-11 EG EG22590A patent/EG18956A/xx active
- 1990-04-11 JP JP2096150A patent/JPH0647548B2/ja not_active Expired - Fee Related
-
1992
- 1992-09-24 GR GR920402116T patent/GR3005794T3/el unknown
-
1994
- 1994-02-22 SG SG27894A patent/SG27894G/en unknown
- 1994-04-28 HK HK39294A patent/HK39294A/en not_active IP Right Cessation
-
1995
- 1995-10-20 CY CY177795A patent/CY1777A/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0316124A2 (en) * | 1987-11-09 | 1989-05-17 | Pfizer Inc. | Ethylated avermectins |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, Vol. 102, 1985, 216821 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FI92015C (fi) | 1994-09-26 |
| OA09203A (fr) | 1992-06-30 |
| NO175882B (no) | 1994-09-19 |
| SG27894G (en) | 1995-03-17 |
| EP0393890B1 (en) | 1992-08-12 |
| FI92015B (fi) | 1994-06-15 |
| DK0393890T3 (da) | 1992-09-28 |
| CN1046282A (zh) | 1990-10-24 |
| GR3005794T3 (enrdf_load_stackoverflow) | 1993-06-07 |
| NO175882C (no) | 1994-12-28 |
| HK39294A (en) | 1994-05-06 |
| AP9000174A0 (en) | 1990-04-30 |
| AU5311990A (en) | 1990-11-08 |
| JPH02290820A (ja) | 1990-11-30 |
| CN1035356C (zh) | 1997-07-09 |
| FI901816A0 (fi) | 1990-04-10 |
| RU1836084C (ru) | 1993-08-23 |
| JPH0647548B2 (ja) | 1994-06-22 |
| NO901637D0 (no) | 1990-04-10 |
| AU609660B2 (en) | 1991-05-02 |
| EG18956A (en) | 1994-04-30 |
| CY1777A (en) | 1995-10-20 |
| NO901637L (no) | 1990-10-12 |
| EP0393890A1 (en) | 1990-10-24 |
| ES2052173T3 (es) | 1994-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1136081B1 (en) | Sustained-release compositions for the parenteral administration of macrolides | |
| EP0535734B1 (en) | Long acting injectable formulations containing hydrogenated castor oil | |
| DE69432982T2 (de) | Pour-on formulierung enthaltend polymerische material, glykole und glyzeriden | |
| EP0413538A1 (en) | Long active injectable formulations containing triacetin | |
| AP133A (en) | Antiparasitical Formulations | |
| US6001822A (en) | Antiparasitic formulations | |
| US6699847B2 (en) | Antiparasitic formulation | |
| CA2014157C (en) | Antiparasitic formulation containing 25-cyclohexyl-avermectin b1 | |
| KR920006913B1 (ko) | 구충제 제형 | |
| KR20020067781A (ko) | 구충용 이버멕틴 주사제 조성물 및 그 제조방법 | |
| MXPA01006175A (en) | Doramectin formulations | |
| BRPI0101090B1 (pt) | Composition for parenteral administration understanding a macrolíde compound of the class of milbemicines |